Pork is one of the most widely consumed meats in the world, accounting for more than a third of meat production worldwide. Infectious diseases remain the biggest threat to the pork industry, resulting in billions of dollars in economic losses [1] . One particularly devastating disease known to lead to the dramatic decline of swine herds and increased pork prices is porcine reproductive and respiratory syndrome (PRRS) [1] . Clinical features of PRRS include massive abortion in sows and weight loss, respiratory disease, and mortality in young pigs. PRRS outbreaks continue to emerge rapidly and with increased virulence; if left untreated, outbreaks will endanger swine industries worldwide.
PRRS is caused by the PRRS virus (PRRSV). Field isolates often differ significantly in
the degree of virulence and pathogenicity, presumably due to a high degree of genetic variation among strains [2] . PRRSV can be broadly divided into two distinct genotypes, Type 1 (European) and Type 2 (North American). Each genotype also contains several subtypes, which are also genetically diverse and lead to immunity limited to the initial infecting genotype, with only partial or no protection from reinfection by other subtypes [3] . Due to genetic diversity and the rapid evolution rate of PRRSV, development of a broadly protective PRRSV vaccine is challenging, but vaccination remains the most effective way to control PRRS. Several types of commercial vaccines, including killed or modified live vaccines, have been widely used [4] .
Current killed vaccines are largely ineffective in preventing both PRRSV infection and disease, so most farms vaccinate their herds with modified live vaccines to control PRRS outbreaks.
Modified live vaccines are shown to reduce disease caused by genetically similar strains, but they provide very limited or no protection against genetically unrelated field isolates [5] . Therefore, broad cross-protection against genetically dissimilar PRRSV strains should be the main consideration for the design of improved PRRSV vaccines.
Adjuvants including oil-in-water emulsions, polymers, and bacterial antigens have been tested in combination with modified live vaccines in an effort to reduce the antigenic load and improve vaccine efficacy [6, 7] . Results from these studies suggest that addition of adjuvant to MLV PRRSV vaccines can lead to increased protection to PRRSV challenge. Peptide hydrogels also might be a promising delivery system for vaccines due to their high water content, polymer network and reversible sol-gel (solution to gel) formation. Peptide hydrogels have been well studied as drug delivery systems, for tissue engineering applications, and in 3-D cell culture and show promising results [8, 9] . We recently developed a novel peptide that can form a flexible nanofiber hydrogel (H9e) and functions as a potent adjuvant for killed H1N1 influenza vaccines [10] . To further characterize the capabilities of the H9e hydrogel, we evaluated H9e as an 
Materials and Methods

Cells, virus and adjuvant preparation
MARC-145 cells were maintained in modified Eagle's medium (MEM) supplemented with 7% fetal bovine serum (FBS) containing penicillin (100U/ml) and streptomycin (100 µg/ml) at 37 °C with 5% CO 2 . For virus infection and titration, MEM supplemented with 2% FBS was used.
Ingelvac PRRS ® modified live virus vaccine (MLV) was purchased from Boehringer Ingelheim Vetmedica Inc (St. Joseph, MO). PRRSV MN184A was a kind gift from Dr. Kay Faaberg (National Animal Disease Center, USDA-ARS, Ames, IA). PRRSV strains VR-2332 (ATCC, Manassas, VA) and MN184A were prepared and titered in MARC-145 cells and stored in aliquots at -80 °C until use. H9e peptide was prepared as previously described with a final concentration of 17.5 mg/ml [10] . PRRS MLV vaccine was resuspended in 50 ml vaccine diluent, provided by the manufacturer, to yield a 2-fold concentrate of vaccine virus. MLV-alone vaccine was then mixed 1:1 with vaccine diluent. A solution of 6 mg H9e with 1.2% porcine serum in diluent/MEM medium was added 1:1 with 2x MLV to prepare MLV+H9e vaccine.
Pigs, vaccination and PRRSV challenge
Thirty-five female/unvaccinated (3 weeks old) Large White-Duroc crossbred PRRSV-free pigs were divided into 7 groups (n = 5) and housed in separate pens within the Large Animal Research Center (LARC) at Kansas State University. These piglets were confirmed sera-negative All animal experiments were approved by the Institutional Animal Care and Use Committee at Kansas State University.
Analysis of serum virus titer
Total RNA was extracted from serum and one-step SyBR Green real-time PCR (Bio-Rad, Hercules, CA) was performed to evaluate the PRRSV ORF7 expression level as previously described [11] . For quantification, total RNA of a known TCID 50 of virus was 10-fold serially diluted and were used to generate a standard curve. The virus quantities of unknown samples were determined by linear extrapolation of the Ct value plotted against the standard curve.
PRRSV-specific and virus neutralizing antibody titration
PRRSV-specific ELISA antibody titers were measured using the Herdcheck Porcine Reproductive and Respiratory Syndrome X3 Antibody Test (IDEXX Laboratories, Westbrook, ME) as described by the manufacturer. Virus neutralizing antibody titer in the serum was analyzed as previously described [11] . Briefly, serum samples were heat-inactivated and serial dilutions were mixed with PRRSV VR-2332 or MN184A viruses. After incubation, the mixtures were transferred to MARC-145 cells and incubated for 72 hours. Cytopathic effect (CPE) was used to determine the end-point titers that were calculated as the reciprocal of the highest serum dilution to neutralize >90% CPE induced by 200 TCID 50 of PRRSV in duplicate wells per sample. the respective challenge PRRSV similar to that described in Ferrari et al. [12] . Cell culture supernatants were analyzed by ELISA for IL-10 cytokine secretion (Invitrogen).
Analysis of cytokine responses
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples by 
Statistical analysis
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of humoral response, cytokine production and viremia among each group were determined by the one-way analysis of variance (ANOVA) followed by post-hoc Tukey's test using Sigmaplot 11 software (Systat Software Inc., San Jose, CA). Differences were considered statistically significant when p<0.05.
Results
H9e adjuvant enhances cross-protection efficacy of MLV to heterologous PRRSV infection in pigs
Our previous studies showed that H9e hydrogel can be a safe, efficacious adjuvant for the killed H1N1 swine influenza vaccines, resulting in significantly higher hemagglutination inhibition titers and antibody titers to swine influenza than immunization with antigen alone [10] . Since H9e acts as a potent adjuvant for killed subunit vaccines, we hypothesized that H9e hydrogels could also work as an adjuvant for a modified live PRRS vaccine. Interestingly, pigs vaccinated with MLV gained significantly less weight than unvaccinated and MLV+H9e vaccinated pigs at 28 DPV (Fig. 1a, b) , suggesting that the un-adjuvanted MLV vaccine virus may cause sub-clinical disease in pigs.
To determine if vaccinated pigs were protected from homologous or heterologous virus challenge, titers of circulating virus were measured 7 days post challenge (DPC). We found that the pigs vaccinated with MLV+H9e were able to significantly clear both the VR-2332 and MN184A strains circulating in the blood 7 days post challenge (7 DPC). Pigs vaccinated with MLV alone were able to significantly clear the homologous VR-2332 virus strain (Fig.1c) . The pigs vaccinated with MLV alone had reduced viral load in the blood after MN184A challenge; however, it was not statistically significant from that in the unvaccinated-challenged group of pigs (Fig. 1d) . Taken together, these results suggest that the addition of H9e adjuvant to PRRSV MLV vaccines can enhance protection against genetically distinct stains of PRRSV.
Pigs vaccinated with MLV+H9e have increased vaccine virus circulation in the blood after vaccination
H9e rapidly forms a gel once it is formulated with MLV. Therefore, we suspect that the H9e nanofiber network may act as a scaffold to prolong vaccine virus entry into the blood or enhance its replication within the host to enhance the vaccine's protective effects. To determine if H9e adjuvant affects the viral load of the vaccine strain of PRRSV in vaccinated pigs, we measured circulating viral load in the serum of all pigs weekly. Interestingly, pigs vaccinated with MLV+H9e started to develop significantly higher levels of circulating virus two weeks after vaccination and reached an average maximum of 5.5-fold (9,057±402 TCID 50 equivalent/ml ) higher virus titers than that in pigs vaccinated with MLV alone (1,638± 625 TCID 50 equivalent /ml) on 21 DPV (Fig. 2a) . By 28 DPV, the MLV virus was eliminated from the blood of pigs in all groups. Therefore, our results suggest that H9e may act to stabilize the MLV virus within the host and thus to increase the exposure of antigen to the host immune system. (Fig.2c) . After homologous VR-2332 viral challenge, pigs vaccinated with MLV+H9e had significantly higher VN titer to VR-2332 and comparable VN titer to MN184A compared with pigs vaccinated with MLV alone (Fig. 2d) . However, all vaccinated pigs developed similar levels of VN titers after heterologous MN184A viral challenge (Fig. 2e) . Therefore, our results show that the addition of H9e hydrogel adjuvant can induce early on-set and enhanced antibody production over vaccinating pigs with MLV alone.
Pigs vaccinated with MLV+H9e hydrogel have increased pro-inflammatory cytokines and reduced immunosuppressive cytokine secretion profiles
Because we found that H9e can improve the humoral immune responses of pigs to the PRRS MLV vaccine, we next assayed the effects of H9e adjuvant on MLV-elicited cytokine profiles. In doing so, sera at 7 DPC were analyzed for the presence of IL-4, IL-8, IL-10, IFN-γ and TNF-α.
As shown in Fig. 3 , the levels of IFN-γ, but not TNF-α, in the sera from MLV+H9e vaccinated pigs was significantly higher than that in pigs vaccinated with MLV-alone after challenge (Fig3a,b) . The levels of IL-4 and IL-8 in sera from pigs vaccinated with MLV+H9e were significantly higher than that from pigs vaccinated with MLV-alone when the pigs were challenged with VR-2332 PRRSV (Fig. 3c, d) . Conversely, the secretion of immunosuppressive cytokine IL-10 in sera of MLV+H9e vaccinated pigs was reduced compared with that in the MLV-alone vaccinated pigs after challenge with both VR-2332 and MN184A (Fig. 3e) . IL-10 expression levels of lung and TBLN MNCs also were analyzed at necropsy (15 DPC). As shown in Fig. 3e , after these cells were re-stimulated with either VR-2332 or MN184A in vitro, reduced IL-10 cytokine levels were observed in the supernatant of lung and lymph node MNCs of the pigs vaccinated with MLV+H9e. Therefore, our results suggest that addition of H9e to MLV vaccine alters cytokine expression profiles.
Pigs vaccinated with MLV+H9e display decreased T-regulatory and increased
Th/memory lymphocyte subpopulations
To verify if the change in cytokine expression patterns was associated with changes in lymphocytes population, the frequencies of T-helper cells, cytotoxic T lymphocyte, Th/memory cells, T-regulatory cells and γδ T cells in blood, lung, and lymph nodes were evaluated using flow cytometry analysis. As shown in Fig. 4 , a significant decrease of the T-regulatory (Treg) lymphocyte population (Fig. 4a) and increase of the Th/memory lymphocyte population (Fig. 4b) was observed in the blood of pigs vaccinated with MLV+H9e than that in pigs vaccinated with MLV alone 4 weeks after vaccination. The decrease of Treg lymphocyte population and increase of Th/memory lymphocyte population were also observed 14 DPC in pigs challenged with homologous VR-2332 or heterologous MN184A PRRSV in blood, TBLN, and lung MNC samples (Fig. 4c, d ). Additionally, we examined Th cells, CTL, γδ T cells and NK cell population before and after challenge and found no significant changes in any groups (data not shown).
Discussion
Current commercial vaccines, both killed virus and modified live, are deficient in protecting swine herds from the consistently evolving field isolates of PRRSV [13] . One approach to improving PRRSV vaccine efficacy is the addition of immunomodulatory adjuvants including water-oil emulsions, aluminum, bacterial components, and polymers to killed or live modified PRRSV vaccines [14] . Interestingly, a new class of adjuvants, nanoparticles, has been shown to increase the cross-protection efficacy of killed PRRSV vaccines. In a recent study by Dwivedi et al, PLGA nanoparticle-entrapped killed PRRSV vaccine induces a cross-protective immune response against heterologous PRRSV challenge via enhanced innate and PRRSV-specific adaptive responses [15] . However, further studies are needed to reduce the cost and complexity of nanoparticle production before nanoparticle-based vaccines can be widely used as commercial products. Some more cost-effect commercial water-in-oil emulsion and polymers adjuvants, such as MontanideTM ISA 15A and Gel01 ST, have also been utilized in live modified PRRSV vaccines [6] . Deville et al. showed that pigs vaccinated with adjuvanted MLV vaccine containing 50% of the antigen load had equivalent protection as pigs vaccinated with full dose of vaccine without the adjuvant.
We recently reported that a biodegradable hydrogel could act as an adjuvant for killed swine influenza vaccines [10] . These previous results show that when H9e hydrogel was used in place of the supplied adjuvant of commercially available FluSure XP (Zoetis Inc), the H9e-adjuvanted vaccine led to significantly higher HAI titers and equivalent IgG antibody responses than the standard formulation of FluSure. Based on these results, we explored the ability of H9e hydrogel to act as an adjuvant for PRRS modified live virus vaccine and here we demonstrated that H9e hydrogels enhanced the vaccine's protective effects for both homologous and heterologous PRRSV infection.
H9e hydrogel forms a biodegradable nanofiber network under physiological conditions [16] . Peptide-based nanofiber networks have been shown to aid in the controlled release of growth factors, therapeutics, and viruses [17] [18] [19] . Therefore, we hypothesized that this nanofiber network could create pockets that the vaccine virus could occupy and thus act as an antigen depot such that PRRS virus is presented slowly to the host immune system. We show here that the H9e had no virucidal effects and was able to facilitate increased PRRS vaccine virus presentation to the host, as shown by enhanced vaccine virus circulation in the blood (Fig. 2a) .
These results suggest high vaccine virus titers in the blood induced by MLV+H9e vaccination may facilitate the generation of an early and robust PRRSV immune response and provide better protection against genetically diverse strains of PRRSV.
In addition to high circulating vaccine virus, pigs vaccinated with MLV+H9e had earlier on-set of PRRS-specific ELISA antibodies and enhanced neutralizing antibody titers to homologous virus. Previous reports have shown that PRRSV-specific antibodies can appear as soon as one week post-vaccination or challenge, however seroconversion is often observed between 14-21 days post exposure [6, 20] . Our results are consistent with these reports and we found that addition of H9e adjuvant reduced the time that most pigs became positive for PRRSVspecific antibodies (Fig.2b and Supplemental Fig.1 ).
In order to gain insight into the immunologic mechanisms employed by the hydrogel adjuvant, cytokine expression levels after PRRSV challenge were compared among vaccinated groups of pigs. We found that the Th1-related cytokine IFN-γ in the sera of pigs vaccinated with MLV+H9e was significantly higher than that of pigs vaccinated with MLV alone after both homologous and heterologous challenges (Fig3a, b) . IFN-γ is a key cytokine that is associated with host cell-mediated immunity (CMI) response, which is secreted by natural killer cells and several different T cell subpopulations, and its expression is often decreased by PRRSV infection [21, 22] . These studies suggest that decreased IFN-γ expression allows PRRSV to evade the host immune response and result in chronic PRRS infections. Interestingly, a recent study using two different PRRSV strains reported that systemic enhancement of IFN-γ further activates natural killers and T cell subpopulations creating a positive feedback loop for the rapid clearance of PRRSV [23] .
Therefore, the elevated production of IFN-γ observed in the pigs vaccinated with H9e+MLV could explain the increased PRRS viral clearance and improved protective immune response we observed.
The expression of inflammatory cytokine IL-8, but not TNF-α, was increased in pigs vaccinated with H9e-MLV when pigs were challenged with homologous VR-2332 virus ( Fig. 3b and d). In previous studies, low serum IL-8 levels are related to persistent PRRSV infection, and elevated IL-8 levels in serum is correlated with the clearance of PRRS virus [24, 25] immune response [29, 30] . In our study, we found that the concentrations of IL-10 in the serum and tissues of pigs vaccinated with MLV alone were consistently higher than that from pigs vaccinated with MLV+H9e (Fig. 3e) . IL-10 is mainly produced by a small subpopulation of T lymphocytes termed T-regulatory cells [31] . Consistent with IL-10 levels, the frequency of T regulatory cells in MLV+H9e vaccinated pigs was dramatically reduced in blood, lung MNCs, and TBLNs post infection (Fig. 4c) . Therefore, it is likely that the reduced T-regulatory cell population and production of IL-10 may contribute to the enhanced Th1 response and efficient elimination of PRRSV after challenge in the pigs vaccinated with MLV+H9e.
CD4
+ CD8 + T cells, which include T-helper, cytolytic, and memory properties, are a major type I IFN-γ cytokine secreting population [32] . In our study, pigs vaccinated with MLV+H9e generated significantly higher Th/memory cell populations both before and after challenge compared to the unvaccinated and MLV vaccinated pigs. This result is consistent with the observation that IFN-γ production is elevated in pigs vaccinated with MLV+H9e. The high frequency of functional T memory cells may contribute to rapid recall response for the quick elimination of subsequent PRRS virus exposure [33] . The ability of H9e adjuvant to shift MLV vaccine from mainly humoral, to a response having both humoral and cell-mediated immune responses suggest that CMI may be important for increased vaccine protection potential. Our results support the notion that MLV+H9e may act to enhance IFN-γ and reduce IL-10 production via increasing Th/memory and decreasing Treg lymphocyte populations, thereby causing a shift to a Th1-type immune response to provide a better protection against PRRSV infection.
We have previously shown that flexible polymer adjuvants such Montanide™ Gel01 ST also can enhance the protective effects of modified live PRRSV vaccines: however, their enhanced protective effects are limited to homologous re-infection [11] . Interestingly, it was demonstrated that the addition of Gel01 adjuvant to MLV vaccine could enhance vaccineinduced antibody-mediated immunity but did not promote a stronger cellular-mediated immunity.
Furthermore, Gel01 adjuvanted MLV did not show improved efficacy in reducing heterologous challenge-induced viremia as compared with MLV alone. Thus, these results and our previous work suggest that the vaccine's ability to generate a cellular-mediated immune response may be essential to mediate its cross-protective efficacy against PRRSV infection.
Conclusion
This study shows that H9e hydrogel as an adjuvant for MLV can improve vaccinationinduced host protection against RRRSV infection by increased circulation of the vaccine virus in the blood, enhanced antibody production, and increased CMI responses. We believe that the addition of H9e hydrogel adjuvant to existing vaccines is an exciting method to improve PRRS live vaccine efficacy. These results encourage us to explore the ability of H9e to work as a universal adjuvant for a broad range of animal vaccines. 
